|
JP3122128B2
(ja)
|
1989-12-21 |
2001-01-09 |
ノボ ノルディスク アクティーゼルスカブ |
ペプチド製剤
|
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
|
EP0796106B1
(en)
*
|
1994-12-23 |
2003-03-19 |
Novo Nordisk A/S |
Protracted glp-1 compositions
|
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
|
US5650386A
(en)
|
1995-03-31 |
1997-07-22 |
Emisphere Technologies, Inc. |
Compositions for oral delivery of active agents
|
|
DE19530865A1
(de)
|
1995-08-22 |
1997-02-27 |
Michael Dr Med Nauck |
Wirkstoff sowie Mittel zur parenteralen Ernährung
|
|
IL128332A0
(en)
|
1996-08-30 |
2000-01-31 |
Novo Nordisk As |
GLP-1 derivatives
|
|
EP1061946B1
(en)
|
1998-02-27 |
2004-04-28 |
Novo Nordisk A/S |
Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
|
|
JP2002512175A
(ja)
|
1998-02-27 |
2002-04-23 |
ノボ ノルディスク アクティーゼルスカブ |
Ｇｌｐ−１類似体の誘導体類
|
|
JP2003522099A
(ja)
|
1998-02-27 |
2003-07-22 |
ノボ ノルディスク アクティーゼルスカブ |
遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
|
|
EP1062240B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
|
CN1317967A
(zh)
|
1998-09-17 |
2001-10-17 |
伊莱利利公司 |
蛋白质制剂
|
|
CA2361716C
(en)
|
1999-02-05 |
2009-04-28 |
Emisphere Technologies, Inc. |
Method of preparing alkylated salicylamides
|
|
AU3957400A
(en)
|
1999-04-16 |
2000-11-02 |
Novo Nordisk A/S |
Dry, mouldable drug formulation
|
|
WO2001092206A1
(en)
|
2000-06-02 |
2001-12-06 |
Emisphere Technologies, Inc. |
Method of preparing salicylamides
|
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
|
US7144863B2
(en)
|
2001-06-01 |
2006-12-05 |
Eli Lilly And Company |
GLP-1 formulations with protracted time action
|
|
CN1332711C
(zh)
|
2002-02-20 |
2007-08-22 |
埃米球科技有限公司 |
施用glp－1分子的方法
|
|
BRPI0411165A
(pt)
*
|
2003-05-14 |
2006-07-11 |
Emisphere Tech Inc |
composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
|
|
CN1787830A
(zh)
*
|
2003-05-14 |
2006-06-14 |
爱密斯菲尔科技公司 |
用于传送肽yy和pyy激动剂的组合物
|
|
KR101241862B1
(ko)
|
2003-09-19 |
2013-03-13 |
노보 노르디스크 에이/에스 |
신규 ｇｌｐ-1 유도체
|
|
MXPA06006745A
(es)
|
2003-12-18 |
2006-08-18 |
Novo Nordisk As |
Compuestos glp-1 novedosos.
|
|
JP2007537142A
(ja)
|
2003-12-18 |
2007-12-20 |
ノボ ノルディスク アクティーゼルスカブ |
アルブミン様物質に結合した新規のｇｌｐ−１類似物
|
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
|
JP2008537873A
(ja)
|
2004-03-31 |
2008-10-02 |
セントカー・インコーポレーテツド |
ヒトｇｌｐ−１ミメティボディ、組成物、方法および用途
|
|
CN1968919A
(zh)
*
|
2004-04-16 |
2007-05-23 |
爱密斯菲尔科技公司 |
用于递送活性剂的8－（2－羟基苯氧基）辛基二乙醇胺和其盐
|
|
WO2005107773A2
(en)
*
|
2004-05-06 |
2005-11-17 |
Emisphere Technologies, Inc. |
Solid dosage form of wetted heparin
|
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
|
MXPA06015049A
(es)
|
2004-07-08 |
2007-02-08 |
Novo Nordisk As |
Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
|
|
US9399054B2
(en)
*
|
2004-07-12 |
2016-07-26 |
Emisphere Technologies, Inc. |
Compositions for delivering peptide YY and PYY agonists
|
|
US8030273B2
(en)
|
2004-10-07 |
2011-10-04 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
|
US7893017B2
(en)
|
2004-10-07 |
2011-02-22 |
Novo Nordisk A/S |
Protracted GLP-1 compounds
|
|
EA011166B1
(ru)
|
2004-12-22 |
2009-02-27 |
Эли Лилли Энд Компани |
Композиции слитых белков-аналогов glp-1
|
|
KR20070090036A
(ko)
|
2004-12-22 |
2007-09-04 |
센토코 인코포레이티드 |
Ｇｌｐ-1 작용제, 조성물, 방법 및 용도
|
|
ES2540929T3
(es)
*
|
2005-02-01 |
2015-07-14 |
Emisphere Technologies, Inc. |
Sistema de administración de retención gástrica y liberación controlada
|
|
JP5755398B2
(ja)
|
2005-03-18 |
2015-07-29 |
ノヴォ ノルディスク アー／エス |
伸長されたｇｌｐ−１化合物
|
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
|
ES2365410T3
(es)
|
2005-04-08 |
2011-10-04 |
Amylin Pharmaceuticals, Inc. |
Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico.
|
|
EP1968645A4
(en)
|
2005-12-22 |
2009-11-04 |
Centocor Ortho Biotech Inc |
HUMAN GLP-1 MIMETIC BODIES AND COMPOSITIONS FOR THE TREATMENT OF ADIPOSITAS AND RELATED DISEASES, METHODS AND APPLICATIONS
|
|
WO2007121318A2
(en)
|
2006-04-12 |
2007-10-25 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
|
US8679540B2
(en)
|
2006-06-09 |
2014-03-25 |
Flamel Technologies |
Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
|
|
AU2007275294A1
(en)
|
2006-07-18 |
2008-01-24 |
Centocor, Inc. |
Human GLP-1 mimetibodies, compositions, methods and uses
|
|
US8501693B2
(en)
|
2006-08-04 |
2013-08-06 |
Amylin Pharmaceuticals, Llc |
Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
|
|
EP2068910A2
(en)
|
2006-08-04 |
2009-06-17 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition
|
|
US20090318353A1
(en)
|
2006-08-25 |
2009-12-24 |
Novo Nordisk A/S |
Acylated Exendin-4 Compounds
|
|
CA2662080C
(en)
|
2006-09-07 |
2012-07-17 |
F. Hoffmann-La Roche Ag |
A process for the manufacture of snac (salcaprozate sodium)
|
|
WO2008070547A1
(en)
*
|
2006-12-01 |
2008-06-12 |
Emisphere Technologies Inc. |
Improved acyclovir formulations
|
|
TW200843794A
(en)
|
2006-12-21 |
2008-11-16 |
Centocor Inc |
Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
|
|
EP1980245A1
(en)
|
2007-04-11 |
2008-10-15 |
Cephalon France |
Bilayer lyophilized pharmaceutical compositions and methods of making and using same
|
|
US20100080829A1
(en)
|
2007-04-11 |
2010-04-01 |
Cephalon France |
Lyophilized pharmaceutical compositions and methods of making and using same
|
|
GB0707662D0
(en)
*
|
2007-04-20 |
2007-05-30 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2009030774A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Truncated glp-1 derivatives and their therapeutical use
|
|
US20100261637A1
(en)
|
2007-09-05 |
2010-10-14 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
EP2190872B1
(en)
|
2007-09-05 |
2018-03-14 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
|
EP2231191A2
(en)
|
2007-12-11 |
2010-09-29 |
ConjuChem Biotechnologies Inc. |
Formulation of insulinotropic peptide conjugates
|
|
JP2009274983A
(ja)
|
2008-05-14 |
2009-11-26 |
Kowa Co |
ニコチン酸アミドを含有する経口医薬組成物
|
|
WO2009158412A2
(en)
|
2008-06-25 |
2009-12-30 |
Endo Pharmaceuticals Solutions Inc. |
Sustained delivery of exenatide and other polypeptides
|
|
RU2494755C2
(ru)
|
2008-08-18 |
2013-10-10 |
Интера Био Лтд. |
Способы и композиции для перорального введения белков
|
|
KR101760953B1
(ko)
|
2008-09-04 |
2017-07-24 |
아밀린 파마슈티칼스, 엘엘씨. |
비-수성 담체를 이용한 서방성 제형물
|
|
US8425968B2
(en)
|
2009-06-19 |
2013-04-23 |
Pepsico., Inc. |
Beverage preservative system containing pimaricin-cyclodextrin complex
|
|
US20120065255A1
(en)
*
|
2009-10-19 |
2012-03-15 |
Nagesh Palepu |
Cabazitaxel formulations and methods of preparing thereof
|
|
NZ599847A
(en)
|
2009-11-13 |
2013-09-27 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist and methionine
|
|
TR201809460T4
(tr)
|
2009-11-13 |
2018-07-23 |
Sanofi Aventis Deutschland |
Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
|
|
EP2512518A1
(en)
|
2009-12-16 |
2012-10-24 |
Novo Nordisk A/S |
Glp-1 receptor agonist compounds with a modified n-terminus
|
|
AU2010339907A1
(en)
|
2009-12-16 |
2012-07-05 |
Nod Pharmaceuticals, Inc. |
Compositions and methods for oral drug delivery
|
|
CA2790708A1
(en)
*
|
2010-02-24 |
2011-09-01 |
Emisphere Technologies, Inc. |
Oral b12 therapy
|
|
WO2011109784A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Formulation of insulinotropic peptide conjugates
|
|
EP2637698B1
(en)
|
2010-11-09 |
2022-04-20 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
|
MX377589B
(es)
*
|
2010-12-16 |
2025-03-10 |
Novo Nordisk As |
Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
|
|
CN102718858B
(zh)
|
2011-03-29 |
2014-07-02 |
天津药物研究院 |
胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
|
|
RU2602601C2
(ru)
|
2011-04-12 |
2016-11-20 |
Ново Нордиск А/С |
Дважды ацилированные производные glp-1
|
|
US20140220134A1
(en)
|
2011-06-24 |
2014-08-07 |
Astrazeneca Pharamceuticals LP |
Method for treating diabetes with extended release formulation of glp-1 receptor agonists
|
|
JP6006309B2
(ja)
|
2011-07-08 |
2016-10-12 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
|
|
EP3542790B1
(en)
*
|
2012-03-22 |
2023-09-13 |
Novo Nordisk A/S |
Compositions comprising a delivery agent and preparation thereof
|
|
CN104203266B
(zh)
*
|
2012-03-22 |
2017-12-26 |
诺和诺德股份有限公司 |
Glp‑1肽组合物及其制备
|
|
JP6517690B2
(ja)
*
|
2012-06-20 |
2019-05-22 |
ノヴォ ノルディスク アー／エス |
ペプチド及び送達剤を含む錠剤製剤
|
|
EP2873422A4
(en)
|
2012-07-10 |
2015-12-30 |
Takeda Pharmaceutical |
PHARMACEUTICAL PREPARATION FOR INJECTION
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
HK1211232A1
(en)
|
2012-12-21 |
2016-05-20 |
Sanofi |
Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
|
|
JP6672140B2
(ja)
*
|
2013-05-02 |
2020-03-25 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１化合物の経口投薬
|
|
CN103405753B
(zh)
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
|
WO2015086732A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues
|
|
TW201609799A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重ｇｌｐ－１／ｇｉｐ受體促效劑
|
|
AR099569A1
(es)
*
|
2014-02-28 |
2016-08-03 |
Novo Nordisk As |
Derivados de insulina y los usos médicos de estos
|
|
US10689429B2
(en)
|
2014-04-07 |
2020-06-23 |
Novo Nordisk A/S |
Double-acylated GLP-1 compounds
|
|
DK3006045T3
(en)
|
2014-10-07 |
2017-07-17 |
Cyprumed Gmbh |
Pharmaceutical formulations for oral administration of peptide or protein drugs
|
|
CN107205949A
(zh)
|
2015-01-29 |
2017-09-26 |
诺和诺德股份有限公司 |
包含片芯和立即释放包衣的用于口服glp‑1给药的药物组合物
|
|
CN107708667A
(zh)
|
2015-06-16 |
2018-02-16 |
太阳医药高级研发有限公司 |
长效利拉鲁肽组合物
|
|
EP3359181A1
(en)
|
2015-10-07 |
2018-08-15 |
Cyprumed GmbH |
Pharmaceutical formulations for the oral delivery of peptide drugs
|
|
WO2017149070A1
(en)
|
2016-03-03 |
2017-09-08 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
|
WO2018065634A1
(en)
|
2016-10-07 |
2018-04-12 |
Cyprumed Gmbh |
Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
|
|
BR112019008565A2
(pt)
*
|
2016-10-31 |
2019-07-09 |
Suda Ltd |
distribuição do agente ativo na mucosa
|
|
AR112015A1
(es)
|
2017-06-09 |
2019-09-11 |
Novo Nordisk As |
Composiciones sólidas para administración oral
|
|
PL3746111T3
(pl)
|
2018-02-02 |
2024-01-15 |
Novo Nordisk A/S |
Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
|
|
RS63523B1
(sr)
|
2018-04-05 |
2022-09-30 |
Sun Pharmaceutical Ind Ltd |
Novi glp-1 analozi
|
|
TWI829687B
(zh)
*
|
2018-05-07 |
2024-01-21 |
丹麥商諾佛 儂迪克股份有限公司 |
包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
|